Savara (NASDAQ:SVRA) was downgraded by equities research analysts at JMP Securities from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, Marketbeat Ratings reports. They presently have a $2.60 price target on the stock. JMP Securities’ price target points to a potential upside of 5.69% from the stock’s current price.

Other research analysts also recently issued reports about the company. LADENBURG THALM/SH SH reissued a “buy” rating and issued a $21.00 price objective on shares of Savara in a research note on Monday, April 1st. Canaccord Genuity set a $22.00 price objective on Savara and gave the company a “buy” rating in a research note on Monday, March 25th. Zacks Investment Research upgraded Savara from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Thursday, April 11th. BidaskClub upgraded Savara from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 4th. Finally, ValuEngine upgraded Savara from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $8.10.

NASDAQ SVRA opened at $2.46 on Thursday. Savara has a one year low of $2.42 and a one year high of $14.06. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.05 and a quick ratio of 12.05. The firm has a market capitalization of $86.71 million, a P/E ratio of -1.91 and a beta of 0.95.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.05. On average, sell-side analysts forecast that Savara will post -1.63 earnings per share for the current year.

In related news, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $9.00, for a total transaction of $70,335.00. Following the completion of the sale, the chief operating officer now owns 184,754 shares in the company, valued at $1,662,786. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO David L. Lowrance sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $9.02, for a total value of $67,650.00. Following the sale, the chief financial officer now owns 2,446 shares of the company’s stock, valued at approximately $22,062.92. The disclosure for this sale can be found here. Insiders sold a total of 75,261 shares of company stock valued at $744,174 in the last quarter. Company insiders own 6.50% of the company’s stock.

A number of hedge funds have recently bought and sold shares of SVRA. FMR LLC purchased a new stake in Savara during the fourth quarter worth approximately $2,830,000. Vanguard Group Inc. lifted its stake in Savara by 23.6% during the third quarter. Vanguard Group Inc. now owns 1,246,240 shares of the company’s stock worth $13,908,000 after purchasing an additional 238,358 shares during the last quarter. Morgan Stanley lifted its stake in Savara by 224.1% during the third quarter. Morgan Stanley now owns 205,560 shares of the company’s stock worth $2,294,000 after purchasing an additional 142,140 shares during the last quarter. Millennium Management LLC purchased a new stake in Savara during the fourth quarter worth approximately $714,000. Finally, Renaissance Technologies LLC purchased a new stake in Savara during the first quarter worth approximately $466,000. Hedge funds and other institutional investors own 45.71% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.